Skip to main content
Download PDF

Gut microbiota in a mouse model of obesity and peripheral neuropathy associated with plasma and nerve lipidomics and nerve transcriptomics

Microbiome volume 11, Article number: 52 (2023) Cite this article

Abstract

Background

Peripheral neuropathy (PN) is a common complication in obesity, prediabetes, and type 2 diabetes, though its pathogenesis remains incompletely understood. In a murine high-fat diet (HFD) obesity model of PN, dietary reversal (HFD-R) to a low-fat standard diet (SD) restores nerve function and the nerve lipidome to normal. As the gut microbiome represents a potential link between dietary fat intake and nerve health, the current study assessed shifts in microbiome community structure by 16S rRNA profiling during the paradigm of dietary reversal (HFD-R) in various gut niches. Dietary fat content (HFD versus SD) was also correlated to gut flora and metabolic and PN phenotypes. Finally, PN-associated microbial taxa that correlated with the plasma and sciatic nerve lipidome and nerve transcriptome were used to identify lipid species and genes intimately related to PN phenotypes.

Results

Microbiome structure was altered in HFD relative to SD but rapidly reversed with HFD-R. Specific taxa variants correlating positively with metabolic health associated inversely with PN, while specific taxa negatively linked to metabolic health positively associated with PN. In HFD, PN-associated taxa variants, including Lactobacillus, Lachnoclostridium, and Anaerotruncus, also positively correlated with several lipid species, especially elevated plasma sphingomyelins and sciatic nerve triglycerides. Negative correlations were additionally present with other taxa variants. Moreover, relationships that emerged between specific PN-associated taxa variants and the sciatic nerve transcriptome were related to inflammation, lipid metabolism, and antioxidant defense pathways, which are all established in PN pathogenesis.

Conclusions

The current results indicate that microbiome structure is altered with HFD, and that certain taxa variants correlate with metabolic health and PN. Apparent links between PN-associated taxa and certain lipid species and nerve transcriptome-related pathways additionally provide insight into new targets for microbiota and the associated underlying mechanisms of action in PN. Thus, these findings strengthen the possibility of a gut-microbiome-peripheral nervous system signature in PN and support continuing studies focused on defining the connection between the gut microbiome and nerve health to inform mechanistic insight and therapeutic opportunities.

Video Abstract

Background

Obesity, prediabetes, and type 2 diabetes are global epidemics affecting hundreds of millions of people worldwide [1, 2]. Driven by overconsumption of a “Western diet” rich in saturated fats that promote metabolic dysfunction (i.e., glucose intolerance and dyslipidemia), these metabolic conditions are associated with several health complications, including peripheral neuropathy (PN) [3, 4]. PN is defined as distal-to-proximal peripheral nerve damage that results in poor gait, increased risk of foot ulceration and amputation, and lower quality of life [5]. Despite intense research, PN pathogenesis remains incompletely understood, and management remains suboptimal.

The gut microbiome has emerged as a plausible link between dietary intake and metabolic and nerve health. Indeed, a Western diet and high-fat diet (HFD) influence gut microbiota and induce dysbiosis [6,7,8]. Additionally, obesity and T2D are associated with a perturbed microbial profile [9,10,11]. In turn, the gut microbiome influences host metabolism by impacting energy utilization, intestinal absorption of macronutrients including lipids, and promoting insulin resistance, hyperglycemia, and dyslipidemia [12,13,14,15,16,17,18,19]. Thus, metabolic symbiosis occurs between the microbiome and host, a relationship modulated by dietary intake.

The microbiome likewise influences nerve health through a microbiome-gut-nervous system axis involving metabolite signaling and the immune system in the context of metabolic dysfunction [20, 21]. Fecal transplant from lean donor mice to recipient animals with HFD-induced obesity reverses small fiber PN and hypersensitivity, accompanied by an improved immune cell profile and an increase in circulating short-chain fatty acids, mainly butyrate [22]. HFD also induces enteric neuropathy by decreasing the density of nitrergic myenteric neurons, changes associated with gut flora restructuring [23]. In humans, T2D patients exhibit a distinct microbiota signature linked to PN status and metabolic status (insulin resistance) [24]. The microbiome may also impact pain in PN through various communication pathways, e.g., immune cells and short-chain fatty acids [22, 25, 26].

Despite several known involved pathways, the precise molecular steps precipitating PN remain elusive. However, the studies indicating potential connections between dietary intake and microbiome structure versus host metabolism and nerve health unlock interesting research avenues. We hypothesize that a microbiome-gut-peripheral nerve axis exists, whereby HFD restructures the gut microbiome which triggers systemic and local metabolic changes that negatively impact peripheral nerve function. This HFD-induced microbiome reorganization and PN relationship suggests that these effects could be reversed through dietary changes. Indeed, we previously demonstrated that dietary reversal (HFD-R) from HFD to a low-fat standard diet (SD) in a HFD obesity mouse model rescues PN phenotypes [27, 28]; however, the impact on the microbiome has not been investigated. Herein, our objective was to leverage SD, HFD, and HFD-R mice to closely examine the microbiome and test the correlations between dietary fat content, gut flora community structure, the plasma and sciatic nerve lipidome, the nerve transcriptome, and PN phenotype in order to gain initial insight into a possible gut-microbiome-peripheral nervous system signature of PN.

Methods

Study design, phenotyping, and biospecimen collection

Mice in the current study (Fig. 1A) represent a subset from a previous larger study [27] that also underwent microbiome assessments and plasma lipidomics. Briefly, a 4-week-old male C57BL/6 J mice (cat. no. 000664, The Jackson Laboratory, Bar Harbor, ME, USA) were split into 3 groups (two groups of n = 16/group; one group of n = 8/group) and fed SD, deriving 10% kcal from fat (cat. no. D12450B, research diets: 10% kcal fat, 20% Kcal protein, 70% kcal carbohydrate, 3.82% energy density), ad libitum for 1 week to allow habituation. At 5 weeks of age, one group (n = 16) was maintained on SD, while the other two groups were switched to HFD, deriving 60% kcal from fat (cat. no. D12492, research diets: 60% kcal fat, 20% kcal protein, 20% kcal carbohydrate, 5.21% energy density). At 16 weeks of age, one HFD group (n = 8) underwent dietary reversal (HFD-R) and was switched back to SD for the remainder of the study until 24 weeks of age. These timelines are consistent with established protocols for generation of mouse models with HFD-induced obesity, prediabetes, and PN [29,30,31]. Mice were maintained and housed at the University of Michigan in a pathogen-free suite following the Committee on Use and Care of Animals guidelines.

Fig. 1
figure 1

Dietary reversal normalizes metabolic and PN phenotypes in mice. A Experimental design depicts standard diet (SD), high-fat diet (HFD), and HFD with dietary reversal (HFD-R) interventions up to 24 weeks (wks) of age in a subset of mice from our larger previously reported study [27]. Asterisks denote datasets from the previous study. B and E Dietary reversal corrects metabolic and neuropathic phenotypes in HFD mice, including B body weight (n = 8–16), C fasting blood glucose (FBG; n = 7–8), D motor nerve conduction velocity (NCV; n = 7–8), and E sensory NCV (n = 7–8) at 24 weeks of age. One-way ANOVA followed by Tukey’s post hoc test for multiple group comparisons; a, adjusted P-value < 0.05 between HFD versus SD; b, adjusted p-value < 0.05 between HFD-R versus SD; c, adjusted P-value < 0.05 between HFD-R versus HFD

Full size image

All mice underwent metabolic and neuropathy phenotyping at 16 and 24 weeks of age in accordance with guidelines by the Diabetic Complications Consortium (www.diacomp.org), per our standard protocol [27]. Metabolic parameters included body weights (BW) and fasting blood glucose (FBG) levels, while neuropathy phenotyping data consisted of sciatic-tibial motor and sural sensory nerve conduction velocities (NCVs) and analysis of intraepidermal nerve fiber density (IENFD). Additional metabolic and neuropathy phenotype data, including glucose tolerance tests (GTT), oxidized low-density lipoprotein (oxLDL), plasma insulin, cholesterol, and triglyceride lipoprotein profiles, and thermal latency, are previously reported [27]. Fecal pellets were additionally collected directly from animals into sterile Eppendorf tubes at 8, 10, 12, 16, 18, 20, 22, and 24 weeks of age, and data from the 8-, 16-, 18-, and 24-week time points are reported. Mice were sacrificed by lethal pentobarbital (Vortech Pharmaceutical, Dearborn, MI, USA) injection at 16 weeks of age (n = 8 SD; n = 6 HFD) or 24 weeks of age (n = 8 SD, HFD, HFD-R) to collect plasma and content from ~ 3 mm of ileum, cecum, or colon under sterile conditions (Fig. 1A, Table S1).

Microbiome profiling and analysis

Collected fecal samples and intestinal content were seeded in a PowerMag Glass Bead Plate (MO BIO Laboratories, Carlsbad, CA, USA) to isolate bacterial DNA using a MagAttract PowerMicrobiome DNA/RNA Kit (Qiagen) and epMotion 5075 liquid handling system. Amplification of the V4 region of the bacterial 16S rRNA gene was performed on an Illumina MiSeq at the University of Michigan Microbiome Core, as previously reported [32].

Raw sequencing reads were filtered with the dada2 R package [33] and then de-replicated and de-noised using derepFastq function with default parameters. After building an amplicon sequence variant (ASV) table and removing chimeras, taxonomy was assigned against the SILVA database (v132) [34] natively implemented in dada2. Uncharacterized ASVs that were not assigned to any known species at the phylum level were classified as not assigned (NA). ASVs with NA or appearing in less than three samples were removed using a prevalence threshold < number of samples × 0.05. Alpha diversity within the samples was measured using different metrics implemented in the phyloseq package [35]. Principal coordinate analysis (PCoA) based on Bray–Curtis dissimilarity metrics was performed with the proportional normalized data to reveal differences between various groups or time points. A permutational analysis of variance (PERMANOVA) using the Adonis function as part of the vegan package (https://CRAN.R-project.org/package=vegan) was performed to test the effect of treatment as a continuous variable on group differences.

Differential abundance analysis was performed with the DESeq2 package [36], and significant ASVs were identified with a p-value < 0.05. Functional profiling was calculated using the Tax4Fun2 package [37]. Multiple testing of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway abundance according to sample groups was performed with the most updated KEGG database. Butyrate-producing bacteria were identified by compiling a taxonomy file that contained the major commensal butyrate-producing bacterial species from the literature [38,39,40,41]. The discovered ASVs from 16S rRNA sequencing were classified against this curated taxonomy file to identify the butyrate-producing bacteria in our dataset.

Untargeted and targeted plasma lipidomics

Plasma (n = 10/group) collected for this study was analyzed by both untargeted and targeted lipidomics at the University of Michigan Regional Comprehensive Metabolomics Resource Center. Lipids were identified from LC/MS/MS untargeted lipidomics data using the LIPIDBLAST program package (http://fiehnlab.ucdavis.edu/projects/LipidBlast) and quantified using MultiQuant software (AB-SCIEX). Missing values were imputed using a K-nearest neighbor (KNN) algorithm, and data were normalized using internal standards. Lipids were measured in both positive and negative ion modes and then merged by their mean values. Differential lipids were identified by unpaired t-test between groups with an adjusted Benjamini–Hochberg p-value < 0.05 as the significance cutoff.

Targeted lipidomics was conducted on plasma and sciatic nerve samples collected from the subset of mice (n = 10) from a previous larger study [27]. All 10 plasma samples were pooled for a total of 350 µl, and lipids were extracted using organic solvents, as previously reported [42]. Triglycerides were then separated on a thin-layer chromatography plate (Merck, Darmstadt, Germany) using hexane:diethyl ether:acetic acid (80:20:1, v/v), as before [27]. Phospholipids, including sphingomyelin, were separated using a solvent mixture of chloroform:methanol:acetic acid:H2O (100:40:12:4, v/v) [43]. Sciatic nerve tissues were pooled, homogenized, and analyzed as described previously [27].

Previous datasets

Longitudinal metabolic measures, as well as PN phenotyping and sciatic nerve transcriptomic and lipidomic datasets at 16 and 24 weeks of age, were collected from SD, HFD, and HFD-R mice in our previous study [27]. Subsets of these data corresponding to mice also followed for the current study were used for correlation analyses with the newly collected microbiome and plasma lipidomic data.

Correlation analysis

Spearman’s correlations were calculated between differential abundance of PN-associated ASVs, which overlapped between HFD versus SD and HFD-R versus HFD from the four gut microbiome niches (ileum, cecum, colon, pellets), to metabolic state and PN, sciatic nerve transcriptomics, and plasma and sciatic nerve lipidomics. Pathway analysis using KEGG and Gene Ontology (GO) annotations were performed on correlated genes in the correlation analysis of sciatic nerve transcriptomics to PN-associated ASVs.

Statistical analysis

All statistical analyses were performed using R software environment (v4.0.1).

Results

Dietary reversal normalizes metabolic and PN phenotypes in mice

Here, we employed a HFD mouse model that develops obesity (Fig. 1B; HFD, green) and prediabetes (Fig. 1C; defined by a FBG between 150 and 180 mg/dL) versus SD mice (red). HFD mice also robustly and consistently develop PN, evidenced by slowed motor (Fig. 1D) and sensory (Fig. 1E) NVCs relative to control SD mice. Placing HFD mice at 16 weeks back on SD diet, i.e., HFD-R mice (blue), reverses metabolic and neuropathic deficits. At the 24-week time point, there were no significant differences in FBG (Fig. 1C) or motor and sensory NVCs (Fig. 1 D–E) between HFD-R and SD mice, indicating rescue of metabolic and nerve dysfunction. These data from the current subset of mice parallel those reported for the full larger study cohort [27].

Dietary reversal shifts microbial structure in obese PN mice

In our first assessment of microbial community structure, we evaluated intragroup alpha diversity. We observed that alpha diversity was significantly higher in the HFD versus HFD-R and SD versus HFD-R groups, as assessed by the Shannon index in all samples (ileum, cecum, colon, pellets) (Fig. 2A). Examining samples by microbial niche, i.e., ileum, cecum, colon, and pellets, independent of time point, revealed consistent alpha diversity differences, especially marked by the lowest alpha diversity in the small intestine in all diet groups (Figure S1A). When samples were combined by time point and diet, independent of niche, diversity decreased within the SD group at the last time point and within the HDF-R group after dietary reversal at 18 and 24 weeks (Figure S1B); on the other hand, there were no differences in alpha diversity under the HFD intervention.

Fig. 2
figure 2

Dietary reversal shifts microbial structure in obese PN mice. A Intragroup microbial diversity is significantly higher in HFD (green; n = 135) versus SD (red; n = 140) and HFD-R groups (blue; n = 84) as assessed by alpha diversity using Shannon index. One-way ANOVA; *P < 0.05, **P < 0.01. B–C Inter-group microbial diversity assessed by beta diversity by ASV clustering by principal coordinate analysis. B Differences between gut microbiota community structure in SD (red), HFD (green), and HFD-R (blue) in the ileum, cecum, colon, and fecal pellets. Samples from HFD-R mice prior to dietary reversal from 8 to 16 weeks (wks) of age clustered with HFD samples. All time points are shown (16 and 24 weeks for ileum, cecum, and colon; biweekly samples from 8 to 12 and 16 to 24 weeks for fecal pellets). C The microbial community structure in fecal pellets at different time points (8, 16, 18, and 24 weeks of age) rapidly responds to HFD, which is reversed by dietary reversal within a short timeframe (SD, n = 7–16, red; HFD, n = 7–16, green; and HFD-R, n = 6–8, blue). D Stacked bar plot of the relative abundance of the most abundant taxa at the phylum level in fecal pellets at 8, 16, 18, and 24 weeks of age (SD, n = 7–16; HFD, n = 7–16; HFD-R, n = 6–8). E Stacked bar plot of the relative abundance of butyrate-producing bacteria at 24 weeks of age

Full size image

Next, we examined gut inter-group diversity between samples, assessed by beta diversity of filtered ASVs. Gut microbiome clustered SD from HFD samples, but HFD-R samples following dietary reversal clustered with SD reflecting similar microbial composition (Fig. 2B, Table S2). Longitudinal analysis of fecal pellets indicated microbial communities rapidly adjust to dietary changes (Fig. 2C). Only 3 weeks after mice were initiated on HFD (i.e., 8 weeks of age), there was a distinct shift in microbial community structure versus SD mice (P = 0.001). Similarly, dietary reversal for 2 weeks (i.e., 18 weeks of age) already restored altered HFD microbial community structure closer to the SD group (P = 0.001). Significant clustering differences between SD and HFD-R versus HFD remained at 24 weeks of age (P = 0.001). Notably, although close, SD and HFD-R remained individually clustered at 24 weeks of age. Ileum, cecum, and colon microbiota showed similar shifts in beta diversity between 16 and 24 weeks (Table S2).

Dietary fat content also altered the relative abundance of the most abundant bacterial phyla, which included Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, Tenericutes, and Verrucomicrobia, in all gut microbiota niches investigated. Specifically, we observed a decrease in Actinobacteria, Bacteroidetes, and Tenericutes under HFD and a concomitant increase in Firmicutes at all time points, which was reversed by dietary reversal (Fig. 2D). At 24 weeks of age, Proteobacteria was drastically lower in the cecum, colon, and fecal pellets of HFD mice, but was not reversed to SD levels in HFD-R samples. Interestingly, we observed increased butyrate-producing bacteria under HFD compared to SD or HFD-R at 24 weeks of age in the small and large intestines (Fig. 2E). However, analysis of HFD-associated butyrate-producing bacterial composition shows that most are pathogenic species.

Dietary reversal shifts microbial taxa signature in obese PN mice

To identify the microbial mediators driving dietary fat-induced changes in gut microbial differences in mice, we identified the most highly differential ASVs in ileum, cecum, colon, and fecal pellets at 16 weeks for HFD versus SD and at 24 weeks for HFD versus SD and HFD-R versus HFD (P < 0.05) (Fig. 3A, Figure S2). We then identified taxa signatures that were restored upon changes in dietary fat composition, i.e., dietary reversal, at 24 weeks of age (overlap between HFD versus SD and HFD-R versus HFD). There were 6 ASVs in the ileum, 35 in the cecum, 25 in the colon (Figure S2), and 21 in the fecal pellets (Fig. 3B). These taxa were defined as diet-sensitive ASVs and were used for subsequent analyses in the study. Although each microbiota niche had a unique signature at 24 weeks of age, we identified two ASVs at the genus level, Enterorhabdus (ASV94) and Bifidobacterium (ASV5) of the phylum Actinobacteria, and one ASV at the family level, Muribaculaceae (ASV3) of the phylum Bacteroidetes, as shared gut bacteria sensitive to dietary fat (Fig. 3D).

Fig. 3
figure 3

Dietary reversal shifts microbial taxa signature in obese PN mice. A Analysis to identify differentially abundant fecal pellet bacteria with DESeq2 between HFD versus SD at 16 weeks of age or between HFD versus SD, HFD-R versus HFD, or HFD-R versus SD at 24 weeks of age (adjusted p-value < 0.05). B Overlap between gut microbial mediators in fecal pellets driving differences between dietary fat at 24 weeks (HFD versus SD, orange; HFD-R versus HFD, purple) represented as a bar plot of log2 fold change (log2FC). ASVs are listed with corresponding genus or family (*) level. C Overlap between KEGG pathway (level 1) mediators in fecal pellets driving differences between dietary fat at 24 weeks (HFD versus SD, orange; HFD-R versus HFD, purple) represented as a bar plot of log2FC. D–E Venn diagrams of unique and common (D) bacterial taxa and E KEGG pathways, which change with dietary fat intake in the mouse gut. Multiple t-testing was used for pathway comparisons, and significant pathways were identified by FDR-adjusted p-value < 0.05. ASV, amplicon sequence variant; wks, weeks

Full size image

Changes in functional gut microbiota composition between dietary interventions in 24-week-old mice were determined by KEGG enrichment analysis. We first identified statistically significant enriched pathways (false discovery rate [FDR] < 0.05) between HFD versus SD and HFD-R versus HFD. We identified 6 overlapping KEGG pathways in the ileum, 46 in the cecum, 19 in the colon (Figure S2), and 25 in the fecal pellets (Fig. 3C). The altered functional categories across microbial niches were mainly related to amino acid biosynthesis and metabolism, insulin resistance/secretion, adipocytokine signaling, bile secretion, and neurotransmitters. The microbiota consistently altered throughout the gut and shared by all niches were the KEGG biological pathways of tyrosine metabolism, arginine and proline metabolism, carbapenem biosynthesis, tropane, piperidine, and pyridine alkaloid biosynthesis, and legionellosis (Fig. 3E).

Diet-sensitive gut bacteria correlate with metabolic state and PN

To correlate the relative abundance of microbiota associated with dietary fat to PN features, we performed correlation analysis (FDR < 0.05) of the diet-sensitive ASVs to metabolic (BW, FBG) and PN (motor and sensory NCVs) phenotyping at 24 weeks of age (Fig. 4). Unique and common correlation patterns were observed between ASVs and phenotyping among the ileum, cecum, colon, and fecal pellets. Overall, taxa correlated with metabolic and neuropathic phenotypes in opposite directions, i.e., increased metabolic parameters with decreased nerve function and decreased metabolic parameters with increased nerve function. When screening for ASVs correlating with all parameters in at least one gut niche, we found nine ASVs had a positive correlation to metabolic measurements (BW, FBG) and negative correlation with nerve function (motor and sensory NCVs), and they increased with HFD and decreased with SD (Fig. 4). The ASVs correspond to the genera Family_XII_AD3011_group (ASV111), Lachnospiraceae_UCG-006 (ASV57), Lachnoclostridium (ASV89), Anaerotruncus (ASV106, ASV196), Enterorhabdus (ASV94), Lactobacillus (ASV120), and Candidatus_Stoquefichus (ASV98) and the family Ruminococcaceae (ASV64). On the other hand, three ASVs, including Lachnoclostridium (ASV142), Lachnospiraceae_NK4A136_group (ASV41), and Bifidobacterium (ASV5), decreased in HFD and increased in SD mice and correlated positively with healthy metabolic and nerve phenotypes.

Fig. 4
figure 4

Diet-sensitive gut bacteria correlate with metabolic state and PN at 24 weeks of age. A Spearman’s correlation heatmap between gut microbial relative abundance at the genus level with metabolic phenotypes [body weight (BW; n = 22–24), fasting blood glucose (FBG; n = 14)] and nerve function [motor nerve conduction velocity (MNCV; n = 21–23), sensory NVC (SNCV; n = 21–23)]. Only ASVs correlating with all parameters in at least one gut niche are shown. ASVs are listed with corresponding genus or family (*) level. Blue ASVs are lower with HFD and correlate negatively with metabolic parameters but positively with PN. Black ASVs are higher with HFD and correlate positively with metabolic phenotypes but negatively with PN. B Summary for (A); + Met/ − PN, correlates positively with metabolic parameters and negatively with PN parameters; − Met/ + PN, correlates negatively with metabolic parameters and positively with PN parameters. Red ASVs are unique for the specified tissues; black ASVs are shared in different tissues. ASV, amplicon sequence variant; C, colon; Ce, cecum; I, ileum; P, pellet

Full size image

Microbial communities associate with plasma and nerve lipidomics and transcriptomics

Next, we were interested in the correlation between long-term systemic and nerve hyperlipidemia to PN and diet-sensitive microbiota. To address this, we performed untargeted lipidomics on plasma that had been banked from a larger cohort of animals whose sciatic nerves were previously analyzed by lipidomics [27]. In plasma, we identified 578 lipids (25 major lipid class) from 76 samples. Lipid-class-based clustering visualized by heatmaps shows a clear increase in sphingomyelins in HFD versus SD mice in plasma at 16 and 24 weeks of age (Fig. 5A). This pattern was reversed in the HFD-R 24-week-old mice which had undergone dietary reversal. On the contrary, plasma triglycerides decreased in the HFD groups but increased after the mice underwent dietary reversal to SD. These observations were confirmed by lipid class aggregates (Fig. 5B) and targeted lipidomics analysis in a separate cohort of animals under the same dietary paradigm (Fig. 5C). The findings in plasma are opposite to what we previously observed in fat surrounding sciatic nerve; in nerve, triglycerides were elevated in HFD but dropped in response to dietary reversal [27], while sphingomyelins were lower in HFD and increased upon reversal to SD (Fig. 5C).

Fig. 5
figure 5

Plasma lipidomics in an obesity PN mouse model and upon dietary reversal. A Clustering of lipid classes identified by untargeted lipidomics of plasma from 16- (left, n = 20) to 24 (right, n = 28)-week-old SD, HFD, or HFD-R mice represented in heatmaps. Purple rectangles outline areas with the most striking differences. B Levels of each lipid species from (A) were Z-score transformed to generate lipid class aggregates from plasma at 16 (top) and 24 (bottom) weeks of age, represented in bar plots of log2(value). C The sum of plasma and sciatic nerve (SCN) [27]-targeted lipidomics (TLC-GC) shows higher sphingomyelins and lower triglycerides versus sciatic nerve [27] from HFD compared to SD and HFD-R animals at 24 weeks of age (n = 10 plasma samples; n = 10 sciatic nerves). D Analysis to identify differentially altered lipids (DALs) between HFD versus SD at 16 weeks of age or between HFD versus SD, HFD-R versus HFD, and SD versus HFD-R at 24 weeks of age (adjusted P < 0.05). E Overlapping DALs from (D) show direction of change for HFD versus SD (orange) and HFD-R versus HFD (purple), represented in a bar plot of log2 fold change (log2FC). Shared lipid species between plasma and sciatic nerve are listed in red text. CE, cholesteryl esters; CL, cardiolipins; CerP, N-hexadecanolsphingosine 1-phosphate; DG, diglycerides; FFA, free fatty acids; MG, 1-acyl-sn-glycerol; MGDG, monogalactosyldiacylglycerol; C24:1 SM, N-15Z-tetracosenoyl-sphing-4-enine; PI-Cer(d18:1/22:0), N-docosanoyl-sphing-4-enine; Cer(d18:1/20:0), N-eicosanoyl-sphing-4-enine; Cer(d18:1/16:0), N-hexadecanoyl-sphing-4-enine; Cer(d18:1/18:0), N-octadecanoyl − sphing-4-enine; Cer(d18:1/24:0), N-tetracosanoyl-sphing-4-enine; PA, phosphatidic acids; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PG, phosphatidylglycerols; PI, phosphatidylinositols; PS, phosphatidylserines; SM, sphingomyelins; TG, triglycerides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; pPC, plasmenyl-phosphatidylcholines; pPE, plasmenyl-phosphatidylethanolamines

Full size image

Individual circulating differentially altered lipids (DALs) were identified by comparing HFD to SD and HFD-R to HFD in 24-week-old mice (Fig. 5 D–E). The levels of 62 DALs changed direction upon dietary reversal; 47 increased and 15 decreased in HFD versus SD, which was reversed in HFD-R versus HFD groups. Lipid species belonging to diglycerides, lysophosphatidylethanolamines, phosphatidylinositols, plasmenyl-phosphatidylethanolamines, and sphingomyelins all increased under HFD and decreased when the animals were switched from HFD to SD.

Next, to determine whether PN-associated bacteria sensitive to dietary fat correlate with altered host lipid profiles, we performed a series of correlation analyses (FDR < 0.05). We first determined the correlation between the relative abundance of ASVs identified in Fig. 4 to plasma lipids that changed upon dietary reversal (Fig. 6A; full correlation Figure S3A). Gut bacteria increasing in HFD, such as Lactobacillus (ASV120), Lachnoclostridium (ASV89), and Anaerotruncus (ASV196), directly correlated with many plasma DALs that increased in HFD, especially sphingomyelins. These ASVs showed inverse correlations with lipids that decreased in response to HFD. A similar pattern was observed with Enterorhabdus (ASV94), Ruminococcaceae (ASV64), Family_XIII_AD3011_group (ASV111), Anaerotruncus (ASV106), and Candidatus stoquefichus (ASV98), although correlations were limited to fewer lipid species. On the other hand, ASVs that increased with SD, such as Bifidobacterium (ASV5) and Lachnospiraceae_NK4A136_group (ASV41), correlated positively with decreasing plasma lipids (triglycerides, free fatty acids, phosphatidylcholines) and negatively with increasing lipids (mostly sphingomyelins) in the cecum, colon, and pellets samples (Fig. 6A). Lachnoclostridium (ASV142) also negatively correlated with increased lipids (mostly triglycerides) but had no correlation with decreasing lipids.

Fig. 6
figure 6

Microbial communities associate with plasma and nerve lipidomics and transcriptomics. A–C Spearman’s correlation analysis heatmaps (FDR < 0.05) of relative abundance of PN-associated gut microbiota sensitive to dietary fat at 24 weeks of age with A plasma differentially altered lipids (DALs) (n = 11 animals), B sciatic nerve DALs [27] (n = 11 animals), and C sciatic nerve differentially expressed genes (DEGs) [27] (n = 11 animals), which are increased (up) or decreased (down) in HFD versus SD. ASVs at the genus or family (*) level that are higher in HFD are listed in black, and ASVs higher in SD are listed in blue. Correlation scale (red, positive; green, negative) is the same for (A–C). D Functional enrichment analysis of 64 increasing and 2 decreasing sciatic nerve DEGs [27] correlating with PN-associated bacteria using gene ontology (GO; left) and Kyoto Encyclopedia of Genes and Genomes (KEGG; right) (P < 0.05). The top ten biological pathways are shown. Bar plots indicate the proportion of DEGs assigned to each term (rich factor), with number of genes in each category indicated. CE, cholesteryl esters; CL, cardiolipins; DG, diglycerides; FFA, free fatty acids; lysoPC, lysophosphatidylcholines; lysoPE, lysophosphatidylethanolamines; PI-Cer(d18:1/22:0), N-docosanoyl-sphing-4-enine; Cer(d18:1/20:0), N-eicosanoyl-sphing-4-enine; Cer(d18:1/18:0), N-octadecanoyl-sphing-4-enine; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; pPE, plasmenyl-phosphatidylethanolamines; SM, sphingomyelins; TG, triglycerides. ASV, amplicon sequence variant; FDR, false discovery rate; C, colon; Ce, cecum; I, ileum; P, pellets

Full size image

To determine whether diet-dependent microbial changes also correlate with lipid species surrounding the sciatic nerve at 24 weeks, we performed correlation analysis between the relative abundance of the PN-associated bacteria and sciatic nerve DALs at 24 weeks of age (Fig. 6B; full correlation Figure S3B) [27]. In contrast to plasma lipidomics, triglycerides and diglycerides around the sciatic nerve were higher in HFD and decreased in response to dietary reversal [27]. We observed positive correlations of bacteria species, such as Lactobacillus, Lachnoclostridium, and Anaerotruncus, to elevated triglycerides and diglycerides in HFD sciatic nerve. Sphingomyelin 41:2 and lysophosphatidylcholine 16:1 were the only lipid species that changed with dietary intervention and overlapped between plasma and sciatic nerve at 24 weeks; however, only lysophosphatidylcholine 16:1 changed in the same direction in both tissues (downregulated in HFD animals and upregulated in SD animals) and negatively correlated with Candidatus stoquefichus (ASV98), Lactobacillus (ASV120), and Anaerotruncus (ASV196) in both plasma and sciatic nerve.

Finally, we performed correlation analysis between the relative abundance of PN-associated bacteria to sciatic nerve transcriptomics profile at 24 weeks of age (Fig. 6C; full correlation Figure S4) [27]. Lactobacillus (ASV120), Lachnoclostridium (ASV89), Family_XIII_AD3011_group (ASV111), Candidatus stoquefichus (ASV98), Ruminococcaceae (ASV64), and Enterorhabdus (ASV94) correlated positively with upregulated genes and negatively with downregulated genes in HFD sciatic nerve. Bifidobacterium (ASV5), Lachnospiraceae_NK4A136_group (ASV41), and Lachnoclostridium (ASV142) correlated negatively with upregulated genes and positively with downregulated genes in HFD sciatic nerve.

GO and KEGG pathway analysis of DEGs that correlated with PN-associated microbiota was enriched in inflammatory response driven by disintegrin and metalloproteinase domain-containing protein 8 (Adam8), haptoglobin (Hp), interleukin-1 receptor antagonist (Il1rn), serum amyloid A 3 (Saa3), and serpin family A member 3 (Serpina3n) (Fig. 6D). Also, lipid and bile metabolism and antioxidant defense pathways were represented by cytochrome P450, family 2, subfamily c, polypeptide 70 (Cyp2c70), gamma-glutamyl transferase 6 (Ggt6), phospholipase A2 group IIE (Pla2g2e), lysophosphatidylglycerol acyltransferase 1 (Lpgat1), and monoacylglycerol O-acyltransferase 2 (Mogat2). These genes mostly correlated positively with ASVs upregulated in HFD, indicating inflammatory, lipid and bile metabolism, and antioxidant defense pathways are linked with PN.

Discussion

In the current study, we leveraged our HFD obesity PN model with a paradigm of dietary reversal to investigate a putative association between the microbiome-gut-peripheral nerve axis and dietary fat intake. We report that even a short duration of high-fat feeding altered microbiome structure in mice, which rapidly reversed when animals were placed back on SD. These changes occurred through microbial ASVs linked to various metabolic and biosynthetic pathways in all four gut niches, i.e., ileum, cecum, colon, and fecal pellets. Correlation analysis further identified specific microbiome signatures linked with metabolic health and nerve function. Correlations between PN-associated ASVs from HFD animals, lipidomics, and transcriptomics data revealed that Lactobacillus, Lachnoclostridium, and Anaerotruncus taxa variants positively correlated with several lipid species, particularly elevated plasma sphingomyelins and sciatic nerve triglycerides. Relationships were also identified between specific PN-associated taxa variants to expression of genes in neuropathic nerves related to pathways involved in PN pathogenesis, including inflammation, lipid metabolism, and antioxidant defense pathways. These data link HFD-mediated PN to the gut microbiome.

Using our HFD mouse model of obesity, prediabetes, and PN and established time points for dietary alteration and phenotyping [29,30,31], we observed a dynamic gut microbial community structure throughout the intestine that was rapidly reshaped within weeks by dietary fat content. Similar findings are reported in humans and rodents within the same timeframe [44, 45], including in response to a 60% kcal HFD [46]. As previously published [47], alpha diversity was lowest in the ileum across gut niches for all diets, i.e., SD, HFD, and HFD-R, compared to large intestine. Across diets, we found alpha diversity was highest in HFD metabolically unhealthy obese mice versus SD and HFD-R. This likely represents community structure shifts in the HFD microbiome, which increase the diversity of deleterious bacteria [48], as observed in HFD mouse gut or fecal pellets by Shannon index [46, 49]. Indeed, closer examination of the individual bacterial composition of the HFD microbiota revealed increased abundance of bacteria belonging to Lachnospiraceae, Oscillospiraceae, and Clostridiaceae, families which contain pathogenic bacteria [50,51,52,53,54].

When we assessed beta diversity, SD samples clustered separately from HFD samples, indicating distinct microbiome structure. HFD-R samples clustered closely with SD samples, but did not ever fully reverse, in line with previously observed reports [7, 23, 46]. Our results examining phyla abundance linked to diet indicate that HFD promotes Firmicutes and reduces Bacteroidetes, i.e., high Firmicutes/Bacteroidetes ratio. Similarly, HFD enhances the proportion of butyrate-producing bacteria. While elevated Firmicutes/Bacteroidetes ratio and butyrate-producing bacteria are generally linked to a healthful status [11], several studies have noted, like our findings, elevated Firmicutes/Bacteroidetes ratio [7, 23, 46, 55, 56] and butyrate-producing metagenes [49] in HFD. Discrepancies among studies may arise from differences in host genetic background [49, 57] or species of Firmicutes phylum [58]. Additionally, the families of bacteria we observed in our bacterial composition analysis (Lachnospiraceae, Oscillospiraceae, and Clostridiaceae) produce butyrate [59,60,61] and thus also likely contribute to the observed increase in butyrate-producing bacteria in HFD mice.

We next investigated specific ASVs, which were identified down to the family or genus level. Several ASVs across the four gut niches were sensitive to diet, i.e., differentially abundant in HFD versus SD and HFD-R versus HFD. Enterorhabdus and Bifidobacterium, of the phylum Actinobacteria, and Muribaculaceae, of the phylum Bacteroidetes, were shared by all gut niches, whereas Clostridium_sensu_stricto_1 was prominent in colon and fecal pellets. In the literature, Bifidobacterium [7, 55, 62] and Clostridium_sensu_stricto genera [55] are lower and Enterorhabdus [62] higher in mouse HFD gut, although, conversely, various Clostridium species, e.g., Clostridium CAG:58 and Clostridium orbiscindens, instead correlate positively with obesity (BMI, visceral fat) [63] and animal-based diet [44] in human microbiome. Thus, species-level differences in diet-induced gut microbial restructuring may be occurring.

We further considered the functional implications of these differential ASV abundances by performing KEGG pathway analysis comparing HFD to SD. Recurrent among the gut niches were tyrosine metabolism, arginine and proline metabolism, carbapenem biosynthesis, tropane, piperidine and pyridine alkaloid biosynthesis, and legionellosis. In the large intestine, the most significant pathway was insulin resistance, whereas in fecal pellets, neurotransmitter pathways and serotonergic and dopaminergic synapse featured prominently. Several studies have shown correlation of insulin resistance with distinct gut microbial communities [15, 16, 56, 63]. Related to insulin resistance, and also represented in the KEGG analyses on cecum, colon, and fecal pellets, were adipokine signaling (same fold-change direction) and insulin secretion (opposite direction). The literature also underscores the relevance of gut microbiome metabolism related to neurotransmitter biosynthesis, e.g., tyrosine, tryptophan, phenylalanine, and glutamate metabolism and serotonin and dopamine signaling, which are central to nervous system health [20].

Although the impact of HFD on gut microbiome structure is well established [7, 23, 44, 46, 49, 55,56,57,58, 63], the effect on peripheral nerve health is less investigated. Thus, after analyzing dietary fat content-induced gut flora changes, we assessed the correlation of microbial ASVs with metabolic parameters and PN phenotypes. Generally, HFD increases BW and FBG and decreases motor and sensory NCVs [27, 28], leading to an inverse relationship in these metabolic parameters to PN phenotype. In the current study, nine ASVs correlated positively with metabolic measurements (BW, FBG) and negatively with nerve function and were elevated in HFD and reduced in SD, while three ASVs that associated negatively with metabolic parameters and positively with nerve function were decreased in HFD and increased in SD. Thus, nerve health correlates with distinct microbiome signatures. Other studies have also noted a microbiome signature of PN in humans [24] and enteric neuropathy in mice [23, 55]. Although ASVs were not provided for direct comparison, similar genera to those identified herein, such as Lactobacillus, Bifidobacterium, and Lachnoclostridium, were among those that differentiated enteric neuropathy [23, 55] and PN [24], among others.

To establish a potential link between diet, PN, and microbiome to specific lipid species, we conducted lipidomics analysis of plasma from 24-week-old SD, HFD, and HFD-R mice, which we combined with our published sciatic nerve lipidomics dataset under the same diet paradigms [27]. Our observations for triglycerides and sphingomyelin showing inverse levels between plasma and sciatic nerve lipids, i.e., in HFD versus SD and HFD-R, agree with reports of elevated plasma/serum sphingomyelins in HFD mice [64, 65] and obese humans [66, 67]. In our correlation analysis of PN-associated ASVs with plasma and sciatic nerve lipids, the most salient associations emerged between elevated circulating sphingomyelins and lower triglycerides in HFD mice, which were negatively linked to certain microbiota species in the cecum, colon, and pellets samples. Bifidobacterium, a beneficial bacterial genus used in probiotics supplements, correlates with improved gut microbiome structure [68,69,70]. Additionally, Bifidobacterium pseudolongum supplements decrease plasma triglyceride levels in HFD mice [70], which would improve metabolic profile. We found gut bacteria increasing in HFD, such as Lactobacillus, Lachnoclostridium, and Anaerotruncus, correlated negatively with several free fatty acid and complex lipid species, including LysoPC 16:1, in both plasma and sciatic nerve. In type 2 diabetes patients, Lachnoclostridium correlated positively with total cholesterol and low-density lipoprotein cholesterol and a poorer metabolic profile [24].

We finally examined microbial correlations to nerve transcriptome. Most PN-associated gut microbiota positively correlated with upregulated sciatic DEGs, although two downregulated DEGs (Acsm3 and Jun) negatively correlated with PN-associated microbiota. Acsm3 is an important enzyme in butyrate metabolism, as it activates medium-chain fatty acids towards mitochondrial β-oxidation [71]. Downregulated Acsm3 in HFD sciatic nerve may potentially be a compensatory mechanism to slow butyrate metabolism in attempts to maintain nerve butyrate levels [22]. Similarly, we observed downregulated Jun, encoding c-Jun, a protein highly expressed in injured Schwann cells [72] and downregulated during myelination in vivo [73].

All other sciatic nerve DEGs correlated positively with gut microbiota and PN phenotypes, indicating an important link between the microbiota and PN. Pathway analysis of the correlated sciatic DEGs in HFD was related to inflammation (included genes Adam8, Saa3, Il1rn, Serpina3n) and lipid, bile, and antioxidant metabolism (Cyp2c70, Ggt6, Pla2g2e, Lpgat1, Mogat2). Notably, IL1rn is involved in granulocyte adhesion and is associated with PN in diabetes db/db murine models [74], and Saa3 is an inflammatory marker of Schwann cell injury in peripheral nerves [75]. Both IL1rn and Saa3 are markers of sterile inflammation, are modulated by gut microbiota [76, 77], and are associated with PN in both ob/ob and db/db mouse models [27, 78,79,80]. Mice with Serpin3 deficiency exhibit neuropathic pain, which can be reversed by exposure to exogenous Serpin3 [81]. We also identified Adam8, which stimulates axonal extension, as a novel target linking the gut microbiota to sciatic PN [82]. Many of the DEGs related to lipid metabolism (Pla2g2e, Lpgat1, Mogat2) have been previously identified in the sciatic nerve of HFD mice and are involved in linoleic acid, phospholipid, and neutral lipid metabolism [27], suggesting a link between gut microbiota and sciatic lipid metabolism.

This study has limitations. First, it was a correlative study, not a causative one, which would require fecal transplants or antibiotic treatment. However, fecal transplants from lean donor mice to recipient mice with HFD-induced obesity reverse PN phenotypes and immune profiles [22], suggesting possible causality between microbiome and PN. Second, our study only involved male mice, which may not identify important findings due to sex differences in lipids [66, 83, 84] and the microbiome [20, 85]. Finally, our HFD model is based on a homogenous mouse C57BL/6 background in an experimental setting. However, genetics influences microbiome [49, 57] and metabolic phenotype [28]; thus, in the real-world setting, intraindividual variation is likely to moderate the relationships identified in this study.

Conclusions

Overall, we report the presence of a PN-associated microbiome signature in response to dietary fat. In correlation analyses, Lactobacillus, Lachnoclostridium, and Anaerotruncus ASVs positively correlated with several lipid species, particularly elevated plasma sphingomyelins and sciatic nerve triglycerides in HFD mice with PN. In sciatic nerve transcriptome, PN-associated ASVs were linked to gene expression related to inflammation, lipid metabolism, and antioxidant defense, intimating a potential gut-microbiome-peripheral nerve system. These findings underscore the importance of microbiota in PN pathogenesis. The identified HFD-associated microbial species could potentially serve as biomarkers to predict PN susceptibility in obese, prediabetic, and diabetic individuals, and clinical studies are warranted to test the correlation between these microbial species and human PN. Additionally, our assessment of dietary impact on microbiota composition shows that a HFD is associated with pathogenic microbiota, while a SD is associated with more beneficial microbiota. This offers insight into novel therapeutic strategies for PN that focus on diets with low-fat content and beneficial microbiota, supplied either via probiotics or fecal microbial transplant. Importantly, manipulation of microbiota has been successfully applied in obese, prediabetic, and diabetic individuals to improve their health and quality of life [86,87,88,89,90]. Our data support the contention that shifting away from a Western diet can delay PN and identify the microbiome as a potential target for therapeutic intervention in PN. Continuing studies focused on defining the connection between the gut microbiome and nerve health are thus warranted.

Availability of data and materials

The raw murine 16S sequencing dataset generated and analyzed in the current study is deposited in NCBI SRA under the BioProject accession number PRJNA700071. All the scripts are available from the corresponding author upon request. Supplementary information is available in Additional file 1.

Abbreviations

Adam8:

Disintegrin and metalloproteinase domain-containing protein 8

ASV:

Amplicon sequence variant

C24:1 SM:

N-15Z-tetracosenoyl-sphing-4-enine

CE:

Cholesteryl esters

Cer(d18:1/20:0):

N-Eicosanoyl-sphing-4-enine

Cer(d18:1/16:0):

N-Hexadecanoyl-sphing-4-enine

Cer(d18:1/18:0):

N-Octadecanoyl − sphing-4-enine

Cer(d18:1/24:0):

N-Tetracosanoyl-sphing-4-enine

CerP:

N-Hexadecanolsphingosine 1-phosphate

CL:

Cardiolipins

Cyp2c70:

Cytochrome P450, family 2, subfamily c, polypeptide 70

D:

Diglycerides

DALs:

Differentially altered lipid

DEG:

Differentially expressed genes

FBG:

Fasting blood glucose

FFA:

Free fatty acids

Ggt6:

Gamma-glutamyltransferase 6

GO:

Gene ontology

HFD:

High-fat diet

HFD-R:

High-fat diet reversal

Hp:

Haptoglobin

Il1rn:

Interleukin-1 receptor antagonist

KEGG:

Kyoto Encyclopedia of Genes and Genomes

LP::

Lysophosphatidylethanolamines

LPC:

Lysophosphatidylcholines

Lpgat1:

Lysophosphatidylglycerol acyltransferase 1

MG:

1-Acyl-sn-glycerol

MGDG:

Monogalactosyldiacylglycerol

Mogat2:

Monoacylglycerol O-acyltransferase 2

NVC:

Nerve conduction velocities

PA:

Phosphatidic acids

PC:

Phosphatidylcholines

PCoAL:

Operational taxonomic units

PE:

Phosphatidylethanolamines

PG:

Phosphatidylglycerols

PI:

Phosphatidylinositols

PI-Cer(d18:1/22:0):

N-docosanoyl-sphing-4-enine

Pla2g2e:

Phospholipase A2 group IIE

PN:

Peripheral neuropathy

pPC:

Plasmenyl-phosphatidylcholines

pPE:

Plasmenyl-phosphatidylethanolamines

PS:

Phosphatidylserines

Saa3:

Serum amyloid A 3

SD:

Standard diet

Serpina3n:

Serpin family A member 3

SM:

Sphingomyelins

TG:

Triglycerides

References

  1. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.

    Article  PubMed  Google Scholar 

  2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.

    Article  PubMed  Google Scholar 

  3. Callaghan BC, Reynolds E, Banerjee M, Chant E, Villegas-Umana E, Feldman EL. Central obesity is associated with neuropathy in the severely obese. Mayo Clin Proc. 2020;95(7):1342–53.

    Article  PubMed  Google Scholar 

  4. Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. Muscle Nerve. 2021;63(3):285–93.

    Article  PubMed  Google Scholar 

  5. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, Bril V, Russell JW, Viswanathan V. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41.

    Article  PubMed  Google Scholar 

  6. Bibbò S, Ianiro G, Giorgio V, Scaldaferri F, Masucci L, Gasbarrini A, Cammarota G. The role of diet on gut microbiota composition. Eur Rev Med Pharmacol Sci. 2016;20(22):4742–9.

    PubMed  Google Scholar 

  7. He C, Cheng D, Peng C, Li Y, Zhu Y, Lu N. High-fat diet induces dysbiosis of gastric microbiota prior to gut microbiota in association with metabolic disorders in mice. Front Microbiol. 2018;9:639.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hernandez-Baixauli J, Puigbò P, Torrell H, Palacios-Jordan H, Ripoll VJR, Caimari A, Del Bas JM, Baselga-Escudero L, Mulero M. A pilot study for metabolic profiling of obesity-associated microbial gut dysbiosis in male Wistar rats. Biomolecules. 2021;11(2):303.

  9. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. The microbiota-gut-brain axis in obesity. Lancet Gastroenterol Hepatol. 2017;2(10):747–56.

    Article  PubMed  Google Scholar 

  10. Gurung M, Li Z, You H, Rodrigues R, Jump DB, Morgun A, Shulzhenko N. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020;51:102590.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.

    Article  CAS  PubMed  Google Scholar 

  12. Ko CW, Qu J, Black DD, Tso P. Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat Rev Gastroenterol Hepatol. 2020;17(3):169–83.

    Article  CAS  PubMed  Google Scholar 

  13. Martinez-Guryn K, Hubert N, Frazier K, Urlass S, Musch MW, Ojeda P, Pierre JF, Miyoshi J, Sontag TJ, Cham CM, et al. Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids. Cell Host Microbe. 2018;23(4):458-469.e455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.

    Article  PubMed  Google Scholar 

  15. Wang H, Lu Y, Yan Y, Tian S, Zheng D, Leng D, Wang C, Jiao J, Wang Z, Bai Y. Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets. Front Cell Infect Microbiol. 2019;9:455.

    Article  CAS  PubMed  Google Scholar 

  16. Liu Y, Wang Y, Ni Y, Cheung CKY, Lam KSL, Xia Z, Ye D, Guo J, Tse MA, Panagiotou G, et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention. Cell Metab. 2020;31(1):77-91.e75.

    Article  CAS  PubMed  Google Scholar 

  17. Zhang PP, Li LL, Han X, Li QW, Zhang XH, Liu JJ, Wang Y. Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharmacol Sin. 2020;41(5):678–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Le Roy T, Lécuyer E, Chassaing B, Rhimi M, Lhomme M, Boudebbouze S, Ichou F, Haro Barceló J, Huby T, Guerin M, et al. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biol. 2019;17(1):94.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Org E, Blum Y, Kasela S, Mehrabian M, Kuusisto J, Kangas AJ, Soininen P, Wang Z, Ala-Korpela M, Hazen SL, et al. Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort. Genome Biol. 2017;18(1):70.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99(4):1877–2013.

    Article  CAS  PubMed  Google Scholar 

  21. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20(2):145–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bonomo RR, Cook TM, Gavini CK, White CR, Jones JR, Bovo E, Zima AV, Brown IA, Dugas LR, Zakharian E, et al. Fecal transplantation and butyrate improve neuropathic pain, modify immune cell profile, and gene expression in the PNS of obese mice. Proc Natl Acad Sci U S A. 2020;117(42):26482–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Nyavor Y, Brands CR, May G, Kuther S, Nicholson J, Tiger K, Tesnohlidek A, Yasuda A, Starks K, Litvinenko D, et al. High-fat diet-induced alterations to gut microbiota and gut-derived lipoteichoic acid contributes to the development of enteric neuropathy. Neurogastroenterol Motil. 2020;32(7):e13838.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wang Y, Ye X, Ding D, Lu Y. Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes. J Int Med Res. 2020;48(9):300060520936806.

    Article  CAS  PubMed  Google Scholar 

  25. Lin B, Wang Y, Zhang P, Yuan Y, Zhang Y, Chen G. Gut microbiota regulates neuropathic pain: potential mechanisms and therapeutic strategy. J Headache Pain. 2020;21(1):103.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cai TT, Ye XL, Yong HJ, Song B, Zheng XL, Cui BT, Zhang FM, Lu YB, Miao H, Ding DF. Fecal microbiota transplantation relieve painful diabetic neuropathy: a case report. Medicine (Baltimore). 2018;97(50):e13543.

    Article  PubMed  PubMed Central  Google Scholar 

  27. O’Brien PD, Guo K, Eid SA, Rumora AE, Hinder LM, Hayes JM, Mendelson FE, Hur J, Feldman EL. Integrated lipidomic and transcriptomic analyses identify altered nerve triglycerides in mouse models of prediabetes and type 2 diabetes. Dis Model Mech. 2019;13(2):dmm042101.

    Article  Google Scholar 

  28. Hinder LM, O’Brien PD, Hayes JM, Backus C, Solway AP, Sims-Robinson C, Feldman EL. Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech. 2017;10(6):717–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Rumora AE, Guo K, Hinder LM, O’Brien PD, Hayes JM, Hur J, Feldman EL. A high-fat diet disrupts nerve lipids and mitochondrial function in murine models of neuropathy. Front Physiol. 2022;13:921942.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Eid SA, Feldman EL. Advances in diet-induced rodent models of metabolically acquired peripheral neuropathy. Dis Model Mech. 2021;14(11):dmm049337.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Sajic M, Rumora AE, Kanhai AA, Dentoni G, Varatharajah S, Casey C, Brown RDR, Peters F, Hinder LM, Savelieff MG, et al. High dietary fat consumption impairs axonal mitochondrial function in vivo. J Neurosci. 2021;41(19):4321–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Seekatz AM, Theriot CM, Molloy CT, Wozniak KL, Bergin IL, Young VB. Fecal microbiota transplantation eliminates Clostridium difficile in a murine model of relapsing disease. Infect Immun. 2015;83(10):3838–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glöckner FO. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013;41(Data issue):D590-596.

    CAS  PubMed  Google Scholar 

  35. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One. 2013;8(4):e61217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wemheuer F, Taylor JA, Daniel R, Johnston E, Meinicke P, Thomas T, Wemheuer B. Tax4Fun2: prediction of habitat-specific functional profiles and functional redundancy based on 16S rRNA gene sequences. Environ Microbiome. 2020;15(1):11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vital M, Karch A, Pieper DH. Colonic butyrate-producing communities in humans: an overview using omics data. mSystems. 2017;2(6):e00130-17.

  39. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, Flint HJ. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000;66(4):1654–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. MBio. 2019;10(1):e02566-e2518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett. 2009;294(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  42. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911–7.

    Article  CAS  PubMed  Google Scholar 

  43. Skipski VP, Peterson RF, Barclay M. Quantitative analysis of phospholipids by thin-layer chromatography. Biochem J. 1964;90(2):374–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–63.

    Article  CAS  PubMed  Google Scholar 

  45. Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. Isme J. 2011;5(2):220–30.

    Article  CAS  PubMed  Google Scholar 

  46. Shang Y, Khafipour E, Derakhshani H, Sarna LK, Woo CW, Siow YL, Karmin O. Short term high fat diet induces obesity-enhancing changes in mouse gut microbiota that are partially reversed by cessation of the high fat diet. Lipids. 2017;52(6):499–511.

    Article  CAS  PubMed  Google Scholar 

  47. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.

    Article  CAS  PubMed  Google Scholar 

  48. Jeffery IB, Lynch DB, O’Toole PW. Composition and temporal stability of the gut microbiota in older persons. Isme J. 2016;10(1):170–82.

    Article  CAS  PubMed  Google Scholar 

  49. Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjaere E, Midtbo LK, et al. High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice. Microbiome. 2017;5(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Carter GP, Cheung JK, Larcombe S, Lyras D. Regulation of toxin production in the pathogenic Clostridia. Mol Microbiol. 2014;91(2):221–31.

    Article  CAS  PubMed  Google Scholar 

  51. Kameyama K, Itoh K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ. 2014;29(4):427–30.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kim K, Lee S, Park SC, Kim NE, Shin C, Lee SK, Jung Y, Yoon D, Kim H, Kim S, et al. Role of an unclassified Lachnospiraceae in the pathogenesis of type 2 diabetes: a longitudinal study of the urine microbiome and metabolites. Exp Mol Med. 2022;54(8):1125–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Moore RJ, Lacey JA. Genomics of the pathogenic Clostridia. Microbiol Spectr. 2019;7(3):GPP3-0033.

  54. Rauz S, Low L, Suleiman K, Bassilious K, Rossiter A, Acharjee A, Loman N, Murray PI, Wallace GR. OP-10 GUT microbiota dysbiosis as a driver of inflammation in ocular mucous membrane pemphigoid. BMJ Open Ophthalmol. 2022;7(Suppl 1):A3.

    PubMed  Google Scholar 

  55. Nyavor Y, Estill R, Edwards H, Ogden H, Heideman K, Starks K, Miller C, May G, Flesch L, McMillan J, et al. Intestinal nerve cell injury occurs prior to insulin resistance in female mice ingesting a high-fat diet. Cell Tissue Res. 2019;376(3):325–40.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Reilly AM, Yan S, Huang M, Abhyankar SD, Conley JM, Bone RN, Stull ND, Horan DJ, Roh HC, Robling AG, et al. A high-fat diet catalyzes progression to hyperglycemia in mice with selective impairment of insulin action in Glut4-expressing tissues. J Biol Chem. 2021;298(1):101431.

  57. Zhang C, Zhang M, Wang S, Han R, Cao Y, Hua W, Mao Y, Zhang X, Pang X, Wei C, et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. Isme J. 2010;4(2):232–41.

    Article  CAS  PubMed  Google Scholar 

  58. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Flaiz M, Baur T, Brahner S, Poehlein A, Daniel R, Bengelsdorf FR. Caproicibacter fermentans gen. nov., sp. nov., a new caproate-producing bacterium and emended description of the genus Caproiciproducens. Int J Syst Evol Microbiol. 2020;70(7):4269–79.

    Article  CAS  PubMed  Google Scholar 

  60. Van den Abbeele P, Belzer C, Goossens M, Kleerebezem M, De Vos WM, Thas O, De Weirdt R, Kerckhof FM, Van de Wiele T. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 2013;7(5):949–61.

    Article  PubMed  Google Scholar 

  61. Vital M, Howe AC, Tiedje JM. Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. mBio. 2014;5(2):e00889.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Li H, Liu F, Lu J, Shi J, Guan J, Yan F, Li B, Huo G. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice. Front Microbiol. 2020;11:512.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, Leeming E, Gibson R, Le Roy C, Khatib HA, et al. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021;27(2):321–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Eisinger K, Liebisch G, Schmitz G, Aslanidis C, Krautbauer S, Buechler C. Lipidomic analysis of serum from high fat diet induced obese mice. Int J Mol Sci. 2014;15(2):2991–3002.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Shon JC, Kim WC, Ryu R, Wu Z, Seo JS, Choi MS, Liu KH. Plasma lipidomics reveals insights into anti-obesity effect of Chrysanthemum morifolium Ramat leaves and its constituent luteolin in high-fat diet-induced dyslipidemic mice. Nutrients. 2020;12(10):2973.

  66. Beyene HB, Olshansky G, Smith AAT, Giles C, Huynh K, Cinel M, Mellett NA, Cadby G, Hung J, Hui J, et al. High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: evidence from two large population cohort studies. PLoS Biol. 2020;18(9):e3000870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Im SS, Park HY, Shon JC, Chung IS, Cho HC, Liu KH, Song DK. Plasma sphingomyelins increase in pre-diabetic Korean men with abdominal obesity. PLoS One. 2019;14(3):e0213285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Azad M, Kalam A, Sarker M, Li T, Yin J. Probiotic species in the modulation of gut microbiota: an overview. BioMed Res Int. 2018;2018:9478630.

  69. Ma T, Jin H, Kwok L-Y, Sun Z, Liong M-T, Zhang H. Probiotic consumption relieved human stress and anxiety symptoms possibly via modulating the neuroactive potential of the gut microbiota. Neurobiol Stress. 2021;14:100294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Bo T-b, Wen J, Zhao Y-c, Tian S-j, Zhang X-y, Wang D-h. Bifidobacterium pseudolongum reduces triglycerides by modulating gut microbiota in mice fed high-fat food. J Steroid Biochem Mol Biol. 2020;198:105602.

    Article  CAS  PubMed  Google Scholar 

  71. De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, Rutgeerts P, Verbeke K. Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflamm Bowel Dis. 2012;18(6):1127–36.

    Article  PubMed  Google Scholar 

  72. Hutton EJ, Carty L, Laurá M, Houlden H, Lunn MP, Brandner S, Mirsky R, Jessen K, Reilly MM. c-Jun expression in human neuropathies: a pilot study. J Peripher Nerv Syst. 2011;16(4):295–303.

    Article  PubMed  Google Scholar 

  73. Parkinson DB, Bhaskaran A, Arthur-Farraj P, Noon LA, Woodhoo A, Lloyd AC, Feltri ML, Wrabetz L, Behrens A, Mirsky R, et al. c-Jun is a negative regulator of myelination. J Cell Biol. 2008;181(4):625–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Hinder LM, Murdock BJ, Park M, Bender DE, O’Brien PD, Rumora AE, Hur J, Feldman EL. Transcriptional networks of progressive diabetic peripheral neuropathy in the db/db mouse model of type 2 diabetes: an inflammatory story. Exp Neurol. 2018;305:33–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Jang SY, Shin YK, Lee HY, Park JY, Suh DJ, Kim JK, Bae YS, Park HT. Local production of serum amyloid a is implicated in the induction of macrophage chemoattractants in Schwann cells during wallerian degeneration of peripheral nerves. Glia. 2012;60(10):1619–28.

    Article  PubMed  Google Scholar 

  76. Reigstad CS, Bäckhed F. Microbial regulation of SAA3 expression in mouse colon and adipose tissue. Gut Microbes. 2010;1(1):55–7.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Rogier R, Ederveen THA, Boekhorst J, Wopereis H, Scher JU, Manasson J, Frambach S, Knol J, Garssen J, van der Kraan PM, et al. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis. Microbiome. 2017;5(1):63.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Hur J, Dauch JR, Hinder LM, Hayes JM, Backus C, Pennathur S, Kretzler M, Brosius FC 3rd, Feldman EL. The metabolic syndrome and microvascular complications in a murine model of type 2 diabetes. Diabetes. 2015;64(9):3294–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. O’Brien PD, Hur J, Hayes JM, Backus C, Sakowski SA, Feldman EL. BTBR ob/ob mice as a novel diabetic neuropathy model: neurological characterization and gene expression analyses. Neurobiol Dis. 2015;73:348–55.

    Article  CAS  PubMed  Google Scholar 

  80. Pande M, Hur J, Hong Y, Backus C, Hayes JM, Oh SS, Kretzler M, Feldman EL. Transcriptional profiling of diabetic neuropathy in the BKS db/db mouse: a model of type 2 diabetes. Diabetes. 2011;60(7):1981–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Vicuña L, Strochlic DE, Latremoliere A, Bali KK, Simonetti M, Husainie D, Prokosch S, Riva P, Griffin RS, Njoo C, et al. The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase. Nat Med. 2015;21(5):518–23.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem. 2004;279(16):16083–90.

    Article  CAS  PubMed  Google Scholar 

  83. Torretta E, Barbacini P, Al-Daghri NM, Gelfi C. Sphingolipids in obesity and correlated co-morbidities: the contribution of gender, age and environment. Int J Mol Sci. 2019;20(23):5901.

  84. Santosa S, Jensen MD. The sexual dimorphism of lipid kinetics in humans. Front Endocrinol (Lausanne). 2015;6:103.

    Article  PubMed  Google Scholar 

  85. Jašarević E, Morrison KE, Bale TL. Sex differences in the gut microbiome-brain axis across the lifespan. Philos Trans R Soc Lond B Biol Sci. 2016;371(1688):20150122.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Barthow C, Hood F, Crane J, Huthwaite M, Weatherall M, Parry-Strong A, Krebs J. A randomised controlled trial of a probiotic and a prebiotic examining metabolic and mental health outcomes in adults with pre-diabetes. BMJ Open. 2022;12(3):e055214.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Ding D, Yong H, You N, Lu W, Yang X, Ye X, Wang Y, Cai T, Zheng X, Chen H, et al. Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients. Front Cell Infect Microbiol. 2022;12:820367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Hasain Z, Raja Ali RA, Ahmad HF, Abdul Rauf UF, Oon SF, Mokhtar NM. The roles of probiotics in the gut microbiota composition and metabolic outcomes in asymptomatic post-gestational diabetes women: a randomized controlled trial. Nutrients. 2022;14(18):3878.

  89. Su L, Hong Z, Zhou T, Jian Y, Xu M, Zhang X, Zhu X, Wang J. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation. Sci Rep. 2022;12(1):1152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Ziegler MC, Garbim Junior EE, Jahnke VS, Lisboa Moura JG, Brasil CS. Schimitt da Cunha PH, Lora PS, Gemelli T. Impact of probiotic supplementation in a patient with type 2 diabetes on glycemic and lipid profile. Clin Nutr ESPEN. 2022;49:264–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Drs. Vincent Young and Ingrid Bergin for expert consultation on microbiome and histological analysis. We also thank Dr. Arun Das for expert advice with the targeted lipidomics analysis and technical assistance from Ms. Maegan Tabbey, Ms. Faye Mendelson, and Mr. John Hayes. The authors also acknowledge Mrs. Elizabeth Taylor for administrative support.

Funding

Funding for this study was provided by the National Institutes of Health (R24DK082841, R21NS102924, U24DK115255, R01ES030049, F32DK112642, K99DK119366), the Novo Nordisk Foundation (NNF14OC0011633), the American Diabetes Association (7–12-BS-045), the Nathan and Rose Milstein Research Fund, the Sinai Medical Staff Foundation Neuroscience Scholar Fund, the Tauber Family Student Internship Program, the University of Michigan Medical School Host Microbiome Core, the Microbiome Explorer Program, the A. Alfred Taubman Medical Research Institute, and the NeuroNetwork for Emerging Therapies.

Author information

Author notes

  1. Kai Guo, Claudia Figueroa-Romero, and Mohamed Noureldein contributed equally.

Authors and Affiliations

  1. Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA

    Kai Guo, Claudia Figueroa-Romero, Mohamed Noureldein, Lucy M. Hinder, Stacey A. Sakowski, Amy E. Rumora, Hayley Petit, Masha G. Savelieff & Eva L. Feldman

  2. Reata Pharmaceuticals, Irving, TX, 75063, USA

    Lucy M. Hinder

  3. Department of Neurology, Columbia University, New York, NY, 10032, USA

    Amy E. Rumora

  4. Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, 58202, USA

    Junguk Hur

Authors
  1. Kai Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Figueroa-Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Noureldein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucy M. Hinder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stacey A. Sakowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amy E. Rumora
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hayley Petit
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masha G. Savelieff
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junguk Hur
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eva L. Feldman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CFR and LMH contributed to the conception and design of the study. MN, KG, MN, LMH, HP, and JH contributed to the acquisition and analysis of data. ELF provided study oversight. MN, CFR, AER, SAS, MGS, and ELF drafted a significant portion of the manuscript or figures. LMH, AER, JH, and ELF secured funding. The authors read and approved the final manuscript.

Authors’ information

Not applicable/section optional.

Corresponding author

Correspondence to Eva L. Feldman.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Supplementary information: Supplementary figures: Figure S1. Alpha diversity across microbiome samples. Figure S2. Dietary reversal shifts microbial taxa signature in obese PN mice. Figure S3. Full correlation analysis for microbial communities to plasma and sciatic nerve lipidomics. Figure S4. Full correlation analysis for microbial communities to plasma and sciatic nerve transcriptomics. Supplementary tables: Table S1. Study microbiome samples. Table S2. Beta diversity in microbiome samples.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, K., Figueroa-Romero, C., Noureldein, M. et al. Gut microbiota in a mouse model of obesity and peripheral neuropathy associated with plasma and nerve lipidomics and nerve transcriptomics. Microbiome 11, 52 (2023). https://doi.org/10.1186/s40168-022-01436-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40168-022-01436-3

Keywords

Microbiome

ISSN: 2049-2618

Contact us